Doriano Fabbro

Research.com Recognitions

• 2023 - Research.com Biology and Biochemistry in Switzerland Leader Award

Overview

Best Publications

• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

  Ellen Weisberg;Paul W. Manley;Werner Breitenstein;Josef Brüggen

  1879
  Citations

• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  Simon D. Harding;Joanna L. Sharman;Elena Faccenda;Christopher Southan

  1832
  Citations

• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  Sauveur-Michel Maira;Frédéric Stauffer;Josef Brueggen;Pascal Furet

  1660
  Citations

• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  Christopher Southan;Joanna L. Sharman;Helen E. Benson;Elena Faccenda

  1101
  Citations

• A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy

  R A Olie;A P Simões-Wüst;B Baumann;S H Leech

  936
  Citations

• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  Ellen Weisberg;Christina Boulton;Louise M Kelly;Paul Manley

  732
  Citations

• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C- raf kinase

  Brett P. Monia;Joseph F. Johnston;Thomas Geiger;Marcel Muller

  720
  Citations

• PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid.

  Gertraud Müller;Mohamed Ayoub;Peter Storz;Jörg Rennecke

  717
  Citations

• In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

  Carlos Garcia-Echeverria;Mark Andrew Pearson;Andreas Marti;Thomas Meyer

  662
  Citations

• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes

  Stephen P.H. Alexander;Doriano Fabbro;Eamonn Kelly;Neil V. Marrion

  642
  Citations

• Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

  Sauveur-Michel Maira;Sabina Pecchi;Alan Huang;Matthew Burger

  599
  Citations

• The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

  Stephen P. H. Alexander;Doriano Fabbro;Eamonn Kelly;Neil Marrion

  554
  Citations

• A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity

  T Meyer;U Regenass;D Fabbro;E Alteri

  552
  Citations

• Trends in kinase drug discovery: targets, indications and inhibitor design.

  Misty M. Attwood;Doriano Fabbro;Aleksandr V. Sokolov;Stefan Knapp;Stefan Knapp

  543
  Citations

• The Concise Guide to PHARMACOLOGY 2017/18: Overview

  Stephen P. H. Alexander;Eamonn Kelly;Neil V. Marrion;John A. Peters

  517
  Citations

• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

  Yiguo Hu;Yuhua Liu;Shawn Pelletier;Elisabeth Buchdunger

  512
  Citations

• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

  Peter Traxler;Peter Roland Allegrini;Ralf Brandt;Josef Brueggen

  500
  Citations

• THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

  Stephen P H Alexander;Doriano Fabbro;Eamonn Kelly;Alistair Mathie

  486
  Citations

• The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

  Sandra W. Cowan-Jacob;Gabriele Fendrich;Paul W. Manley;Wolfgang Jahnke

  468
  Citations

• Allosteric inhibitors of Bcr-abl–dependent cell proliferation

  Francisco J Adrián;Qiang Ding;Taebo Sim;Anastasia Velentza

  465
  Citations